Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34

Benzinga Newsdesk www.benzinga.com Negative 68.7%

Neg 68.7% Neu 0% Pos 0%

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers the price target from $43 to $34.